Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate J W, Mertens K, van Mourik J A
Department of Blood Coagulation, The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Lancet. 1994 Jun 18;343(8912):1535-6. doi: 10.1016/s0140-6736(94)92939-4.
Abnormal coagulation factor V may underlie the thrombotic events associated with resistance to activated protein C (APC). We analysed 27 consecutive patients with documented idiopathic (recurrent) thromboembolism for the occurrence of point mutations within the APC sensitive regions of blood coagulation factor V. In 10 patients we observed a single basepair mutation resulting in a substitution of Arg506 to Gln. This mutation was significantly linked to in-vitro resistance to APC in these subjects. This mutation at Arg506 of factor V may form the molecular basis for the thrombotic events associated with APC resistance.
异常的凝血因子V可能是与活化蛋白C(APC)抵抗相关的血栓形成事件的潜在原因。我们分析了27例连续记录的特发性(复发性)血栓栓塞患者,以检测凝血因子V的APC敏感区域内点突变的发生情况。在10例患者中,我们观察到单个碱基对突变,导致精氨酸506被谷氨酰胺取代。在这些受试者中,该突变与体外对APC的抵抗显著相关。凝血因子V的精氨酸506处的这种突变可能构成与APC抵抗相关的血栓形成事件的分子基础。